Chen Chien-Li, Liou Jyh-Ming, Lu Tsong-Ming, Lin Yi-Hsien, Wang Chin-Kun, Pan Tzu-Ming
Department of Research and Development Division, SunWay Biotech Co., Ltd., Taipei, Taiwan.
Division of Gastroenterology and Hepatology, Department of Internal Medicine, National Taiwan University Hospital, College of Medicine, National Taiwan University, Taipei, Taiwan.
Heliyon. 2020 Sep 22;6(9):e04979. doi: 10.1016/j.heliyon.2020.e04979. eCollection 2020 Sep.
Vigiis 101-LAB capsules are produced from the fermentation of subsp. NTU 101. We tested effects of Vigiis 101-LAB capsules I or II (5 or 10 billion CFU/day, respectively) on gut microflora in clinical trial I, and on peristalsis, immunity, and anti-oxidative capacity in clinical trial II, during a 4-week randomized, double-blind, placebo-controlled, adaptive-design study. In trial I, 36 subjects were divided into capsule I and placebo groups. After 4 weeks, spp. and spp. counts were significantly higher in the feces of treatment subjects, with increases of 4.01- and 4.25-fold, respectively. In trial II, 52 subjects were divided into capsule II and placebo groups. After 4 weeks, the treatment group was found to have improved motility, decreased food transit time, and significantly increased immunoglobulin G, immunoglobulin M, and antioxidant activity. Thus, daily administration of Vigiis 101 capsule II can improve peristalsis, immunity, and anti-oxidative capacity.
Vigiis 101-LAB胶囊由NTU 101亚种发酵制成。在一项为期4周的随机、双盲、安慰剂对照、适应性设计研究中，我们在临床试验I中测试了Vigiis 101-LAB胶囊I或II（分别为50亿或100亿CFU/天）对肠道微生物群的影响，并在临床试验II中测试了其对蠕动、免疫力和抗氧化能力的影响。在试验I中，36名受试者被分为胶囊I组和安慰剂组。4周后，治疗组受试者粪便中的 菌属和 菌属数量显著更高，分别增加了4.01倍和4.25倍。在试验II中，52名受试者被分为胶囊II组和安慰剂组。4周后，发现治疗组的蠕动能力有所改善，食物通过时间缩短，免疫球蛋白G、免疫球蛋白M和抗氧化活性显著增加。因此，每日服用Vigiis 101胶囊II可改善蠕动、免疫力和抗氧化能力。
